• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

    5/21/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email
    • Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible
    • New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients

    ST LOUIS, May 21, 2025  /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to patients. Through direct negotiations with the medications' manufacturers, Evernorth has ensured that patients' monthly cost will not exceed $200.

    Evernorth Health Services (PRNewsfoto/Evernorth Health Services)

    "We are reimagining pharmacy benefits to reduce costs and better serve patients," said Adam Kautzner, Pharm D, President of Evernorth Care Management and Express Scripts. "This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals." 

    This initiative fills a critical need in the market by offering savings, choice and predictability to both patients and health plan sponsors.

    Benefits for Patients:

    • Lower Monthly Copays than Cash Programs: The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient's annual deductible.
    • Meaningful Savings: Patients can save as much as $3,600 per year compared to buying these medications directly from manufacturers or through consumer programs.
    • Enhanced Safety and Efficacy: By accessing WEGOVY® or ZEPBOUND® through Evernorth's pharmacy benefit, patients will benefit from FDA-approved medications and Express Scripts' robust safety checks designed to reduce negative or adverse drug interactions.
    • Simplified Approval and Access: The prior authorization processes accompanying the new offering will be simplified and automated for faster access.
    • Choice of Pharmacies: Patients can select from a broad network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy, staffed by clinicians with specialized knowledge in GLP-1s for enhanced support.

    Benefits for Employers & Other Health Plan Sponsors:

    • Significant Cost Reduction: Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications.
    • Offering Patient Options: Health plan sponsors can ensure that patients have access to the medication that works best for them, without compromising affordability or clinical safety.

    "As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and we're making it easier than ever for health plan sponsors to cover GLP-1s for weight loss," said Harold Carter, PharmD, senior vice president of trade relations at Express Scripts. "This is how we deliver on our promise to put patients first - by making innovative medicines more accessible, at a lower cost, while providing patients and physicians choices in this fast-evolving market."

    Evernorth has the most extensive suite of GLP-1 solutions available with this new addition, which also includes:

    • EncircleRx, a financial model with more than 9 million enrolled lives that has saved health plans $200 million dollars since 2024.
    • EnReachRx, a high-touch patient support clinical model for dispensing GLP-1 prescription medications.

    About Evernorth Health Services

    Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE:CI), or third-party partners. Learn more at evernorth.com.

    Media Contact:

    Justine Sessions

    [email protected]

    860-810-6523

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-launches-new-benefit-option-that-drives-lower-net-cost-for-weight-loss-medicines-and-limits-patient-cost-to-no-more-than-200-per-month-302462363.html

    SOURCE Evernorth

    Get the next $CI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    3/12/2026$358.00Mkt Perform → Outperform
    Bernstein
    10/14/2025$370.00Buy
    Goldman
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $CI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kates Jamie G was granted 814 shares and covered exercise/tax liability with 132 shares, increasing direct ownership by 40% to 2,368 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:20:05 PM ET
    $CI
    Medical Specialities
    Health Care

    Officer Neville Everett was granted 5,280 shares, covered exercise/tax liability with 1,400 shares and sold $496,636 worth of shares (1,719 units at $288.91), increasing direct ownership by 62% to 5,670 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:18:57 PM ET
    $CI
    Medical Specialities
    Health Care

    EVP, Global CIO Koka Durga Prasad was granted 3,177 shares and covered exercise/tax liability with 220 shares, increasing direct ownership by 68% to 7,281 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    3/3/26 7:19:26 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cigna Group

    SCHEDULE 13G/A - Cigna Group (0001739940) (Subject)

    3/26/26 2:23:23 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by The Cigna Group

    DEFA14A - Cigna Group (0001739940) (Filer)

    3/13/26 4:39:25 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by The Cigna Group

    DEF 14A - Cigna Group (0001739940) (Filer)

    3/13/26 4:36:18 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Cigna Group upgraded by Bernstein with a new price target

    Bernstein upgraded The Cigna Group from Mkt Perform to Outperform and set a new price target of $358.00

    3/12/26 8:38:26 AM ET
    $CI
    Medical Specialities
    Health Care

    Goldman initiated coverage on The Cigna Group with a new price target

    Goldman initiated coverage of The Cigna Group with a rating of Buy and set a new price target of $370.00

    10/14/25 8:47:37 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group downgraded by Bernstein with a new price target

    Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

    2/6/25 7:05:01 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Announces Appearance at the TD Cowen 46th Annual Health Care Conference

    BLOOMFIELD, Conn., March 2, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced that Ann Dennison, Executive Vice President and CFO of The Cigna Group, and Adam Kautzner, President of Evernorth Care Management and Express Scripts, will present at the TD Cowen 46th Annual Health Care Conference today, March 2, 2026, in Boston, MA. The Cigna Group's presentation is expected to begin at approximately 1:50 p.m. ET. A live webcast of the presentation will be available at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Invest

    3/2/26 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend

    Total revenues for 2025 increased 11% to $274.9 billionShareholders' net income for 2025 was $6.0 billion, or $22.18 per shareAdjusted income from operations1 for 2025 was $8.0 billion, or $29.84 per share2026 adjusted income from operations1 is projected to be at least $7.950 billion, or at least $30.25 per share2Board of Directors declared an increase in the quarterly dividend to $1.56 per shareBLOOMFIELD, Conn., Feb. 5, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported 2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses.

    2/5/26 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group's Fourth Quarter 2025 Earnings Release Details

    BLOOMFIELD, Conn., Jan. 13, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2025 financial results on Thursday, February 5, 2026, and will host a conference call the same day. Fourth quarter 2025 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 02052026 Replay (866) 405-7290 (Domestic) (203) 369-0603 (

    1/13/26 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Leadership Updates

    Live Leadership Updates

    View All

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

    BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of MPC and Chairman, President and Chief Executive Officer of MPLX. Prior

    6/2/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by The Cigna Group

    SC 13G - Cigna Group (0001739940) (Subject)

    11/12/24 9:55:14 AM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/13/24 5:02:29 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/9/24 8:50:20 AM ET
    $CI
    Medical Specialities
    Health Care